Johnson & Johnson to Acquire Ambrx Biopharma to Advance Next-Gen Oncology Therapeutics

Johnson & Johnson (JNJ) has agreed to acquire Ambrx Biopharma (AMAM) in an all-cash merger valued at approximately $2.0 billion. Ambrx specializes in synthetic biology for next-gen antibody drug conjugates (ADCs), offering a unique approach to targeted oncology therapeutics. The deal enhances JNJ's capabilities and introduces Ambrx's proprietary ADC technology, aiming for efficient cancer cell elimination with minimized side effects.